3,105 search results for “cancer drug discovery initiatief” in the Public website
-
Transforming data into knowledge for intelligent decision-making in early drug discovery
Promotor: A.P.IJzerman Co-promotor: A. Bender
-
Target Discovery
The goal of target discovery is to identify and validate proteins and biological pathways that are involved in the disease process. Modulating these target proteins and pathways with small molecules, therapeutic proteins or other biomolecules (e.g. mRNA) could deliver an effective and safe drug or v…
-
RNA splicing in breast cancer progression
In this thesis, we aimed to better understand the underlying mechanisms involved in TNBC progression and metastasis formation and discover new targets to reduce breast cancer related deaths.
-
Evani Lachmansingh
Science
e.t.lachmansingh@liacs.leidenuniv.nl | +31 71 527 2727
-
Harnessing zebrafish xenograft models for ocular melanoma treatment discovery
The aim of this thesis was to develop novel treatment strategies for different types of eye melanoma utilizing zebrafish models. We first establish orthotopic and ectopic xenograft models for uveal and conjunctival melanoma by engraftment of the immortalized cells derived from these tumors into zebrafish…
-
Drug research
In the Drug Research theme, we primarily work with rodents. Rodents, such as mice, are one of the most common laboratory animals. These small mammals are easily housed and exhibit a rapid rate of reproduction.
-
Precision modeling of breast cancer in the CRISPR era
The molecular mechanisms that instigate a healthy cell to become malignant are fueled by (epi)genetic alterations in so-called driver genes.
-
Discovery of FLT3 inhibitors for the treatment of acute myeloid leukemia
The disease acute myeloid leukemia (AML) is characterized by fast progression and low survival rates.
-
Novel immunomodulatory drugs for tuberculosis treatment
Can drugs that target host signaling pathways be used to eradicate antibiotic-resistant bacteria?
-
Novel regulators of prostate cancer stem cells and tumor aggressiveness
Promotor: R.C.M. Pelger Co-Promotor: G. van der Pluijm
- Leiden Academic Centre for Drug Research
-
Cancer and heredity
Some people are predisposed to develop cancer. Mutations in genetic material that increase a person’s chances of developing cancer can already be present at birth. Researchers are closely examining these mutations to learn more about how cancer begins to develop.
-
PROTEOMINING: a novel proteomics-based pipeline for drug and enzyme discovery in filamentous actinomycetes
Can a new proteomics workflow be developed to link genes and gene clusters to bioactive molecules, identify novel compounds and enhance the production in the Streptomyces lividans enzyme?
-
Cancer Pathogenesis and Therapy
Cancer represents a formidable current and future global health challenge. The LUMC medical research profile Cancer Pathogenesis and Therapy charges this challenge by developing and implementing innovative patient-tailored, multimodal diagnostic methods and treatment modalities.
-
Phenotypic screening with 3D cell-based assays
Traditional drug discovery approaches have been hampered by (in vitro) cell-culture models that poorly represent the situation in the human body.
-
Drug-Related Homicide in Europe
Drug-related homicide (DRH) has the potential to act as a valuable indicator of wider drug-related crime. Yet DRH remains a knowledge gap within this broader field of study.
-
Discoveries at Leiden Science
From the largest numbers to the smallest molecules and from the oldest galaxies up to the latest algorithms, explore our standout discoveries and most inspiring collaborations from the past year!
-
BRCA1-associated breast cancer: finding new weapons for an old villain
ᅟ
-
Leiden Academic Centre for Drug Research
Drug development is a complex process in which many parties work together. Every day, the researchers at LACDR devote their energies to developing drugs that are new, better, more efficient and easier to produce. And thus to the millions of patients who know all too well why this research in Leiden…
-
Development of novel anti-cancer strategies utilizing the zebrafish xenograft model
In this thesis, we will utilize embryonic zebrafish tumour models to understand the interaction between engrafted human cancer cells and macrophages from the host, test drug administration modalities and anti-cancer efficacies of newly-developed PDT and PACT compounds, and test a light-triggered liposomal…
-
Identification of novel targets in prostate cancer progression
Promotor: Prof.dr. B. van de Water, Co-promotor: E.H.J. Danen
-
Upconverting nanovesicles for the activation of ruthenium anti-cancer prodrugs with red light
Promotor: E. Bouwman, Co-promotor: S. Bonnet
-
Drug safety Sciences
Our research in the area of safety sciences aims to increase the mechanistic understanding of cellular toxicity of drugs and, in a broader sense, chemicals.
-
Computational Approaches to Disease, Signaling and Drug Targets
The Minor Computational Approaches to Disease, Signaling and Drug Targets (CADSDT) is focused on fundamental scientific research required for discovery of new drug targets and development of new drugs.
-
PI3K signaling and adherens junctions in invasive lobular breast cancer
Invasive lobular carcinoma (ILC) is the second most common type of breast cancer.
-
Towards improved drug action : target binding kinetics and functional efficacy at the mGlu2 receptor
During the course of drug discovery translational steps are made.
-
Leiden discoveries
From the Big Bang to superconductivity. Many ground-breaking discoveries have been made in Leiden University’s long history.
-
Discovery of Reversible Monoacylglycerol Lipase Inhibitors
Monoacylglycerol lipase (MAGL) is the principal enzyme responsible for hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG). MAGL inhibition provides several potential therapeutic opportunities, including anti-nociceptive, anti-inflammatory and anti-cancer activity.
-
Pulling the strings on anti-cancer immunity
Promotores: J. Jonkers, K.E. de Visser
-
Classical conditioning to improve immunotherapy in cancer
Can the conditioning paradigm be used for checkpoint inhibition cancer treatment?
-
Systems pharmacology-based translational drug pharmacokinetics
High-throughput holistic preclinical screens are increasingly used in drug discovery, to assess both drug efficacy and drug safety.
-
Novel target engagement biomarkers for better drug candidates
Is is possible to better predict the validity of drug candidates?
-
To explore the drug space smarter: Artificial intelligence in drug design for G protein-coupled receptors
Over several decades, a variety of computational methods for drug discovery have been proposed and applied in practice. With the accumulation of data and the development of machine learning methods, computational drug design methods have gradually shifted to a new paradigm, i.e. deep learning methods…
-
Using zebrafish to target the Achilles’ heel of cancer
Exploiting metabolic vulnerabilities to identify anticancer compounds in zebrafish synthetic lethality screens.
-
Inhibitor discovery of phospholipases and N-acyltransferases
In this thesis an activity-based probe was discovered that could visualize the activity of PLAATs. With an optimized gel-based ABPP assay in hand, screening of a compound library led to the discovery of alpha-ketoamides as a hit for PLAAT3.
-
Discovery of novel inhibitors to investigate diacylglycerol lipases and α/β hydrolase domain 16A
Promotor: H.S. Overkleeft, Co-promotor: M. van der Stelt
-
Night of Discoveries
The Night of Discoveries is an annual event in Leiden, focusing on science and culture. The Young Academy Leiden is a recurring contributor to the Night of Discoveries.
-
Oncode Accelerator launched: patients at the centre of innovative cancer drug development
Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process.
-
Using insertional mutagenesis to identify breast cancer drivers and therapy resistance genes in mice
In this thesis, we used genetically engineered mouse models to identify genes and pathways that are involved in ILC formation and in the development of resistance to FGFR-targeted therapy.
-
This Week's Discoveries
Scientists from the Faculty of Science present recent discoveries to colleagues of various fields. In a 15-minute talk, a colleague of the Faculty of Science presents his or her ongoing research. The presentations are aimed at a broad audience.
-
Masullo & Morisi, The Human Costs of the War on Drugs
Citizens in multiple crime-ridden countries strongly support the militarization of security—that is, placing the military in charge of traditional policing duties. Yet, we know little about the determinants of such support. Do people approve of militarization even in the face of human fatalities? Political…
-
Zebrafish: a new engraft model to study Ewing sarcoma progression
Can zebrafish provide a fast, sensitive in vivo vertebrate model for identifying novel mechanisms of Ewing sarcoma progression and for development of new anticancer compounds in a time- and cost-effective manner?
-
synergistic effects of Chinese herbal medicine and natural compounds on cancers
What are the biological effects of Chinese herbal medicine in regulation of cancer cell metastasis?
-
Dynamics of TNFalpha signaling and drug-related toxicity
In previous studies at our laboratory it was demonstrated that drug exposure of HepG2 cells can lead to an altered TNFα-induced NF-κB oscillatory phenotype, concurrent with a synergistically increased sensitivity for TNFα-induced apoptosis.
-
Reverse engineering of drug induced QT(c) interval prolongation: Towards a systems pharmacology approach
Promotor: M. Danhof Co-promotor: O.E. Della Pasqua
-
Prediction of human gut (colon cancer) target site concentrations and PKPD relationships
The advanced insights obtained for the CNS PBPK model development are currently used to develop advanced mathematical models for drug distribution prediction in other body tissues protected by barriers, such as the gut. The gut PBPK model will be linked to drug effects for treatment of colon cancer.
-
Smart chemistry rids anti-cancer drugs of serious side effects
Researchers of the Leiden University Medical Centre (LUMC) and the Leiden Institute of Chemistry have made an important discovery about the commonly used anti-cancer drug doxorubicin. They have found a way to reduce its side effects without sacrificing the effectiveness of the medication. This is encouraging…
-
Microfluidics for high-throughput liposome formulation for personalized cancer vaccination
Liposomes hold great promise for peptide-based personalized cancer vaccination, especially when administered intradermally. However, current liposome preparation methods are very time consuming (resulting in long development times per formulation), whereas personalized cancer vaccination requires very…
-
Role of leukocytes in metastasis formation in a zebrafish
How do macrophages and neutrophils contribute to metastatic onset?
-
Liposome-based synthetic long peptide vaccines for cancer immunotherapy
Promotores: Wim Jiskoot; Ferry Ossendorp